golimumab, the anti-integrin therapies, natalizumab and vedolizumab, and the recently approved interleukin-12/23 inhibitor, ustekinumab. Infliximab, natalizumab, and vedolizumab are given as intravenous infusions, whereas the others are given as subcutaneous injections.
Despite the overall efficacy of biological therapies, patients often require changes in biological agents over the course of their illness. Common reasons for changing biological agents include lack of response (primary nonresponse), loss of response (secondary nonresponse), adverse medication reactions, poor adherence, and inconvenience. Rates of primary nonresponse vary from 20% to 40% in clinical trials to 10% to 20% in studies of daily clinical practice. 2 Rates of secondary nonresponse have been more difficult to define given many studies have not clearly delineated between true worsening of IBD activity from other causes of "active" symptoms like irritable bowel syndrome, bile-salt diarrhea, and infection. Adverse reactions to these medications may include injection or infusion reactions, drug induced lupus, dermatological reactions, or serious infectious complications. Patient preferences also play a role in discontinuing and/ or changing drug treatment, as in a Swiss study, if given a choice, patients preferred the convenience of biologicals given through a subcutaneous injection to those given through an intravenous infusion. 3 Although the armamentarium of treatments for IBD is growing, given the young age of onset of the disease and the often life-long need for treatment, it is important to optimize the use of our available therapies by understanding why these drugs are stopped earlier than we would hope. Therefore, in a multicenter VA cohort of IBD patients, we sought to evaluate the rate of and reasons for discontinuing biological agents, and to identify risk factors for their discontinuation.
MATERIALS AND METHODS

Study Setting and Design
We performed a retrospective cohort study across 4 VA hospital systems; the VA North Texas Healthcare System (Dallas, TX), the Michael E. DeBakey Veterans Affairs Medical Center (Houston, TX), the VA Ann Arbor Healthcare System (Ann Arbor, MI), and the Hunter Holmes McGuire VA Medical Center (Richmond, VA). The institutional review boards of all 4 facilities approved this study.
Study Variables and Case Identification
Patients with verified IBD who were started on biological therapy (infliximab, adalimumab, certolizumab pegol, golimumab, natalizumab, or vedolizumab) by a provider at one of the participating VA medical centers were identified. We reviewed the medical records of patients with IBD seen at one of the 4 participating VA medical centers between 1999 and 2009 (Houston, VA and Ann Arbor, VA), 1999 to 2014 (North Texas, VA), and 1998 to 2015 (Richmond, VA). Patients with IBD were initially identified at the Ann Arbor, VA, the Houston, VA, and the Richmond, VA by the presence of either ICD-9 codes for CD (555.x) or UC (556.x). Patients with IBD at the Dallas VA were identified from a prospectively maintained institutional review board-approved database of approximately 450 patients followed at that medical center. Manual chart review at all institutions was then performed for each patient with suspected IBD to confirm the diagnosis of IBD based on available clinical, endoscopic, histologic, and radiographic information. Data regarding biological use, IBD type, behavior, location, age at diagnosis, sex, and race were extracted from chart review. IBD characteristics and behavior were classified according to the Montreal Classification.
We defined drug response by the persistence of use of the biological agent at 6 months.
Statistical Analysis
Continuous parameters are reported as mean 6 SD, and discrete parameters were reported as n and percent (%). MannWhitney U tests were computed for comparisons of continuous variables, and Fisher exact tests and Pearson chi-square tests were computed for nominal variables. Multiple logistic regression analyses were performed to assess the predictive associations between demographic variables, clinical and medication variables, and persistence of use of the biological agent at 6 months. Multicollinearity diagnostics were computed and assumptions were met for all regression analyses. Analyses were performed using SPSS 22.0 for Windows.
RESULTS
Across 4 VA hospital systems, we identified 1969 patients with IBD. Of these patients with IBD, 256 (13%) were treated with 346 courses of biological therapy (256 patients were treated with 1 agent, 71 with 2 agents, 13 with 3 agents, 5 with 4 agents, and 1 with 5 agents). Of these patients with IBD who were treated with a biological, 59 were diagnosed with UC, 195 with CD, and 2 with indeterminate colitis (Table 1) .
Rates of Early Biological Discontinuation
Of the patients who were treated with their first course of a biological, 55 (21.5%) stopped their biological early (within the first 6 months of treatment). Most patients were treated with infliximab and/or adalimumab (Table 2) , reflecting earlier market availability of these agents. For patients receiving any course of biological, 82 (24%) stopped their biological early. When comparing the rates of early biological discontinuation by the number of previous exposures to the various biological agents available for IBD, the rates of early discontinuation were lowest for those patients using their first biological (Fig. 1) . Furthermore, we evaluated the rates of early biological discontinuation between patients who initiated their biological at a young age (,65) or elderly age ($65 yrs) and found no differences in the rates of biological discontinuation (10.7% of those with early discontinuation were $65 yrs versus 12.9% of those who continued 
Differences in Disease Characteristics
There were no differences in type of IBD (CD versus UC), race, sex, age at biological initiation, age at diagnosis, disease duration, active use of tobacco, presence of perianal disease in those with CD, extent of disease in UC, or baseline C-reactive protein or albumin between patients who discontinued their biological early as compared with those who continued their biological beyond 6 months (Table 1) . For patients with CD, patients with ileocolonic disease distribution, as opposed to ileal only or colonic only disease, or a nonstricturing nonpenetrating disease phenotype were associated with a lower likelihood of early biological discontinuation. Furthermore, for all patients with IBD, the concomitant use of a thiopurine lowered the likelihood of early biological discontinuation, whereas the use of a 5-ASA increased the likelihood for early biological discontinuation.
Predictors of Biological Discontinuation
Multiple logistic regression analyses were performed to identify potential predictors of persistence at 6 months. Predictors explored were disease type (UC or CD), race, sex, age at diagnosis, disease duration, 5-ASA use, thiopurine use, glucocorticoid use (methotrexate use was not included because of the small numbers of patients who used methotrexate and persisted at 6 months), C-reactive protein, albumin, and tobacco use at the initiation of the biological. The predictive model of persistence revealed that the use of 5-ASA at the start of the biological was significantly associated with a lower likelihood of persistence, even after controlling for the other variables in the model (adjusted odds ratio ¼ 0.36, P ¼ 0.004). Patients who used 5-ASA were 64% less likely to continue their biological beyond 6 months. Conversely, the use of a thiopurine at the start of the biological was significantly associated with a higher likelihood of persistence, even after controlling for the other variables in the model (adjusted odds ratio ¼ 2.81, P ¼ 0.004). Thus, the odds of persistence for patients who used a thiopurine were 2.8 times greater than for patient who did not use a thiopurine. The other factors explored including albumin, C-reactive protein and status of tobacco use were not predictive of persistence.
Reasons for Early Biological Discontinuation
The most common reason for early biological discontinuation was primary nonresponse; 36% for first biological users, 40% for second biological users, and 60% for third biological users ( Table 4 ). The second most common reason for early biological discontinuation was because of an adverse reaction, most frequently an infusion reaction or an injection site reaction.
DISCUSSION
In this multicenter VA cohort study, we evaluated the rates of early biological discontinuation in our veteran patients with IBD and found that 24% stopped their biologicals within the first 6 months of use. If they were receiving their first course of biologicals, the rate was slightly lower at 21.5%, but not statistically different. These rates are considerably lower than rates reported in patients with psoriasis who were treated with a biological where 46% discontinued treatment by 12 months. 4 On the other hand, when compared with rates of biological discontinuation for patients with rheumatoid arthritis, the rates in our study were similar with 21% of rheumatoid arthritis patients discontinuing therapy by 6 months. 5 Similar to these studies in psoriasis and rheumatoid arthritis, we found no difference in the rates of discontinuation overall or with the drug as their first biological between the choice of treatment with infliximab or adalimumab. The number of patients using biologicals other than infliximab or adalimumab was too small for adequate comparisons.
One of the predictors of early drug discontinuation identified in our study was not being treated with a concomitant thiopurine. This supports previous studies that have found concomitant treatment with a thiopurine to increase treatment efficacy of an anti-TNF and to reduce immunogenicity. 6, 7 Interestingly, the use of a 5-ASA was also found to be independently associated with an increased risk for early discontinuation of a biological. The reason for the negative association with 5-ASA is less clear. It is possible that 5-ASA use could be a marker of more severe disease if these were added for patients failing other therapies or it may be possible that taking a 5-ASA decreased compliance because of a higher pill burden. Interestingly, on univariate analysis, we also noted that patients with ileocolonic disease location or a nonpenetrating, nonstricturing phenotype were less likely to discontinue therapy early.
Contrary to studies in patients with psoriasis and rheumatoid arthritis, there was no difference in drug discontinuation rates between men and women, possibly because this was a predominately male veteran population (14% women). Also, as opposed to a study from an academic tertiary referral center by Desai et al 8 looking at rates of discontinuation of anti-TNF therapy in older patients, we found no difference in rates of discontinuation in our older (.65 yrs) patients. Interestingly, the Desai study noted that the rates of infections were much higher in their elderly patients as opposed to their younger patients. Therefore, one possible explanation for the lower rates of drug discontinuation in our elderly population could be lower rates on concomitant steroid use in our population (38% in our patients $65 yrs versus 57% in the Desai study) and/or less severe disease.
The most common reasons for drug discontinuation were primary nonresponse (40.2%) or an adverse drug reaction (29.3%). These rates and causes (lack of efficacy or adverse events) are similar to what is reported in a meta-analysis of a number of studies that included rheumatologic patients on biologicals. 5 Limitations of our study include its retrospective design. Moreover, because the study population is predominately men, the generalization of the results to women is less clear. Further, our cohort of veterans is older with the average age of starting a biological in the mid-40s and 13% of patients being aged 65 or older at the time anti-TNF therapy was started. On the other hand, our study has a number of strengths. It is a multicenter US study and one of the first to look at rates of discontinuation and reasons for discontinuation in patients with IBD. Although our use of anti- TNF overall for our patients (13% of the total IBD cohort) is low, this is more representative of a nonreferral center cohort and more applicable to general practice. Moreover, although we relied on drug persistence as a marker of drug response, we also performed individual chart reviews on all patients to further assess drug response and to collect detailed data on why the patients discontinued their drugs when they were no longer being prescribed.
In conclusion, in a large multicenter VA population, we found that 24% of patients who are prescribed a biological stop their treatment early, most commonly for primary nonresponse or for an adverse drug reaction. Consideration should be given to treating patients with a concomitant thiopurine if at all possible, as we found this reduces the likelihood of early discontinuation.
